PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32951572-3	2020	In 2003, the first anti-tumor gene therapy drug rAd-p53 (recombinant human p53 adenovirus), trade name Gendicine , was approved by the China Food and Drug Administration (CFDA) for treatment of head and neck squamous cell carcinoma (HNSCC) in combination with radiotherapy.	gendicine	103-112	tumor protein p53	Homo sapiens	52-55	
32951572-3	2020	In 2003, the first anti-tumor gene therapy drug rAd-p53 (recombinant human p53 adenovirus), trade name Gendicine , was approved by the China Food and Drug Administration (CFDA) for treatment of head and neck squamous cell carcinoma (HNSCC) in combination with radiotherapy.	gendicine	103-112	tumor protein p53	Homo sapiens	75-78	
29338444-1	2018	Gendicine (recombinant human p53 adenovirus), developed by Shenzhen SiBiono GeneTech Co. Ltd., was approved in 2003 by the China Food and Drug Administration (CFDA) as a first-in-class gene therapy product to treat head and neck cancer, and entered the commercial market in 2004.	gendicine	0-9	tumor protein p53	Homo sapiens	29-32	
27843742-1	2016	To compare clinical curative effects and toxicity of recombinant human adenovirus-p53 injection (rAd-p53, Gendicine) combining chemoradiotherapy (CRT)/radiotherapy (RT) with those obtained with CRT/RT alone in nasopharyngeal carcinoma (NPC).	gendicine	106-115	tumor protein p53	Homo sapiens	82-85	
20679889-1	2010	The objective of this study is to explore the safety, efficacy, and administration method of the recombinant adenovirus p53 gene (rAd-p53, or gendicine) in the treatment of pulmonary metastasis tumor from advanced hepatocellular carcinoma (HCC).	gendicine	142-151	tumor protein p53	Homo sapiens	120-123	
16188130-1	2005	OBJECTIVE: To evaluate the efficacy and safety of recombinant adenovirus-p53 gene (Gendicine) therapy combined with radiotherapy for head and neck squamous-cell carcinoma (HNSCC).	gendicine	83-92	tumor protein p53	Homo sapiens	73-76	
16188130-10	2005	The apparent improved results of combined therapy with Gendicine and radiation suggest that p53 gene therapy has promising therapeutic potential in cancer treatment.	gendicine	55-64	tumor protein p53	Homo sapiens	92-95	
24457472-4	2014	The patients in the treatment group were given arterial infusion of p53 gene (Gendicine, Shenzhen Sibiono GeneTech Co, Ltd) with Gendicine (10vp) combined with hydroxycamptothecin (20 mg), once a week, for a course continuously for 3 weeks.	gendicine	78-87	tumor protein p53	Homo sapiens	68-71	
24457472-4	2014	The patients in the treatment group were given arterial infusion of p53 gene (Gendicine, Shenzhen Sibiono GeneTech Co, Ltd) with Gendicine (10vp) combined with hydroxycamptothecin (20 mg), once a week, for a course continuously for 3 weeks.	gendicine	129-138	tumor protein p53	Homo sapiens	68-71	
19882171-1	2010	OBJECTIVE: The purpose of our study was to evaluate the feasibility and treatment outcomes of recombinant adenovirus-p53 (rAd-p53, trademarked as Gendicine) combined with fractionated stereotactic radiotherapy (fSRT) in treatment of primary hepatocellular carcinoma (HCC).	gendicine	146-155	tumor protein p53	Homo sapiens	117-120	
19318914-4	2009	The patient was first treated with adenovirus-mediated wild-type p53 gene (Ad-p53, gendicine) combined with oxaliplatin (200 mg) and transcatheter arterial chemoembolization or transcatheter arterial chemotherapy for two cycles.	gendicine	83-92	tumor protein p53	Homo sapiens	65-68